Neurocognitive Therapies and Translational Research Webinar Series: Psychedelic Therapies for Psychiatric Disorders: Introduction and Early Results
Basic neuroscientific research on the mechanisms underlying cognitive, affective, and social processes have been slow in penetrating real-world psychology/psychiatry clinics. This is a missed opportunity for maximizing and advancing our understanding of core patterns of psychopathology and treatment response in neuropsychiatric disorders. This series will bring together members from the neuroscience, medical, and psychiatry/psychology communities to translate basic science findings into real-world clinical practice.
March 15, 2022 at 9:00 AM PST/12:00 PM EST/16:00 UTC (other time zones)
“Psychedelic Therapies for Psychiatric Disorders: Introduction and Early Results”
Josh Woolley, MD, PhD
Neurocognitive Therapies and Translational Research Webinar Series:
- To evaluate promising neuroscientific findings in the areas of emotion, socioemotional learning and development, cognition, and therapeutic change that have significant potential to improve prevention and intervention efforts for mental illness.
- To recognize common barriers to the translation and adoption of basic science in real-world clinical practice.
- To articulate the benefits of integrating neuroscientific research in clinical practice in terms of prevention, assessment, and treatment for neuropsychiatric disorders.
Speaker: Josh Woolley, MD, PhD.
Angela Fang, PhD
Judy Callan, PhD RN
Maria Kryza-Lacombe, PhD
Greg Siegle, PhD
Andrew Peckham, PhD
Rudi De Raedt, PhD
Michael Thase, MD
Conflict of Interest Disclosure:
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh designates this [replace with applicable format: live webinar activity for a maximum of 1 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP office maintains responsibility for the content of the programs.
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 1.00 APA
- 1.00 Attendance